14 results on '"Skosnik, Patrick D."'
Search Results
2. List of Contributors
- Author
-
Abadie-Guedes, Ricardo, primary, Abi-Dargham, Anissa, additional, Abulseoud, Osama A., additional, Acevska, Jelena, additional, Adan, Ana, additional, Aguilar, María A., additional, Akhgari, Maryam, additional, Ali, Robert, additional, Anderson-Mooney, Amelia J., additional, Anees, Muhammad, additional, Arenas, M. Carmen, additional, Arndt, Jamie, additional, Ascheri, Daniele, additional, Ashraf, Nida, additional, Ashton, Maxie, additional, Asimaki, Olga, additional, Aubry, Jean-Michel, additional, Aujla, Harinder, additional, Awad, A. George, additional, Awara, Mahmoud A., additional, Bagues, Ana, additional, Balhara, Yatan P.S., additional, Bambico, Francis, additional, Barrio-Real, Laura, additional, Bartlett, Selena E., additional, Basavarajappa, Balapal S., additional, Basu, Aniruddha, additional, Bau, Claiton H.D., additional, Beattie, Matthew C., additional, Becker, Benjamin, additional, Beer, Anton L., additional, Behera, Deepak, additional, Benaiges, Irina, additional, Bergen-Cico, Dessa, additional, Bergeson, Susan E., additional, Berrettini, Wade H., additional, Bertoglio, Leandro J., additional, Bockman, Charles S., additional, Borgwardt, Stefan, additional, Bourque, Josiane, additional, Bozkurt, Muge, additional, Brennan, Katharine Alexandra, additional, Briggs, Hilary, additional, Brooks, Samanth J., additional, Bulcão, Rachel Picada, additional, Burkhardt, Ute, additional, Butler, Tracy R., additional, Cabrera, Eduardo Rodrigues, additional, Caldirola, Daniela, additional, Callaghan, Russell C., additional, Callegari, Elza, additional, Caloca, María J., additional, Campos, Alline C., additional, Cannizzaro, Carla, additional, Cape, Gavin, additional, Carnell, Benjamin L., additional, Caso, Javier R., additional, Cendron, Lucas Henrique, additional, Chang, Yun-Hsuan, additional, Cheng, Gordon L.F., additional, Chen, Kao Chin, additional, Chopra, Kanwaljit, additional, Chow, Tony C.H., additional, Cico, Rachael, additional, Cook, Jason B., additional, Coppola, Maurizio, additional, Cortes-Briones, Jose A., additional, Cousijn, Janna, additional, Crist, Richard C., additional, Crocker, Candice E., additional, Danielson, Kirsty, additional, Dasilva, Miguel, additional, Dave, Malay, additional, De Biasi, Mariella, additional, de Carvalho, Cristiane R., additional, De Guio, François, additional, De Ridder, Dirk, additional, Dhiman, Sonia, additional, Diaferia, Giuseppina, additional, Diana, Marco, additional, DiFranza, Joseph R., additional, Dimitrovska, Aneta, additional, Dinh-Williams, Le-Anh, additional, Djurendic-Brenesel, Maja, additional, Dodd, Jonathan N., additional, Dodge, Neil C., additional, Drew, Paul D., additional, Drucker Colín, Rene, additional, Dujmovic, Irena, additional, Dutra Arbo, Marcelo, additional, Edwards, Scott, additional, Etemadi-Aleagha, Afshar, additional, Evren, Cuneyt, additional, Fang, Juan, additional, Fernández-Rodríguez, Camino, additional, Filipovic, Radmila, additional, Finsterer, Josef, additional, Fitzgerald, Megan L., additional, Fogaça, Manoela V., additional, Forero, Diego A., additional, Fouad Moselhy, Hamdy, additional, Freitas, Marco Antonio de, additional, Galletly, Cherrie, additional, García-Bueno, Borja, additional, Gatley, Jodi M., additional, Germanaud, David, additional, Gifford, Roger S., additional, Glue, Paul, additional, Gobbi, Gabriella, additional, Goicoechea, Carlos, additional, González-Arnay, Emilio, additional, González-Reimers, Emilio, additional, González-Sarmiento, Rogelio, additional, Gowing, Linda, additional, Grieve, Kenneth L., additional, Guedes, Rubem Carlos Araújo, additional, Guerri, Consuelo, additional, Guimarães, Francisco S., additional, Guller, Leila, additional, Harland, Jennifer, additional, Hashemi, Seyyed A., additional, Hashemizadeh, Shiva, additional, He, Bei, additional, Hernández-López, Salvador, additional, Hickle, Tyson, additional, Hill, Shirley Y., additional, Holgate, Joan, additional, Huang, Wei, additional, Huang, Wei-Lieh, additional, Hunt, Nicholas J., additional, Hurlemann, René, additional, Iannone, Giuseppe, additional, Idrees, Fariha, additional, Idrees, Jawaria, additional, Ikeda, Kazutaka, additional, Ivanashvili, Nato, additional, Ivanov, Iliyan, additional, Jacobson, Joseph L., additional, Jacobson, Sandra W., additional, Järbe, Torbjörn U.C., additional, Jiang, Y.L., additional, Jokar, Farzaneh, additional, Kane, Cynthia J.M., additional, Kangiser, Megan, additional, Karpyak, Victor, additional, King, Jean A., additional, Kivell, Bronwyn M., additional, Kiyatkin, Eugene A., additional, Klein, Jochen, additional, Klima, Michelle L., additional, Kodirov, Sodikdjon A., additional, Korostynski, Michal, additional, Kreek, Mary Jeanne, additional, Kulevanova, Svetlana, additional, Kumar, Santosh, additional, Langguth, Berthold, additional, Leal, Mirna Bainy, additional, Lee, Sheng-Yu, additional, Lee, Tatia M.C., additional, Leikaif, John, additional, Lin, Shih-Hsien, additional, Lin, Yu-Hsuan, additional, Liu, Xiu, additional, Lorenzetti, Valentina, additional, Lu, Ru-Band, additional, Machaalani, Rita, additional, Maldonado-Devincci, Antoniette, additional, Mangin, Jean-François, additional, Mangoura, Dimitra, additional, Manning, Patrick, additional, Marcu, Jahan P., additional, McCabe, Simon, additional, McGinn, M. Adrienne, additional, McKinney, Diana L., additional, McLaughin, Ryan, additional, McLaughlin, Ian, additional, Meintjes, Ernesta, additional, Midde, Narasimha M., additional, Mihailescu, Stefan, additional, Miñarro, José, additional, Mondola, Raffaella, additional, Leslie Morrow, A., additional, Mota, Nina R., additional, Newcorn, Jeffrey, additional, Nishizawa, Daisuke, additional, Nobrega, José N., additional, Nona, Christina N., additional, Nuñez, Nicolas, additional, Nylander, Ingrid, additional, O’Brien, Jessica W., additional, Oliva, Francesco, additional, Palm, Sara, additional, Papini, Mauricio R., additional, Park, Byung Lae, additional, Pascual, María, additional, Pedraza, Juan, additional, Perna, Giampaolo, additional, Picci, Rocco Luigi, additional, Piechota, Marcin, additional, Pilija, Vladimir, additional, Pinto, Charles, additional, Potvin, Stéphane, additional, Prasad Rawat, Jagdeo, additional, Preedy, Victor R., additional, Priddy, Brittany M., additional, Przewlocki, Ryszard, additional, Raghav, Jimit G., additional, Rajendram, Rajkumar, additional, Rajendram, Roshanna, additional, Rao, P.S.S., additional, Ray, Anirban, additional, Rezayof, Ameneh, additional, Rivadulla, Casto, additional, Rodríguez-Arias, Marta, additional, Rossato, Luciana Grazziotin, additional, Rovaris, Diego L., additional, Ruby, Christina L., additional, Sakellaridis, Nikos, additional, Salman, Saad, additional, Santolaria-Fernández, Francisco, additional, Sarkar, Siddharth, additional, Schechter, Jason B., additional, Schmidt, André, additional, Scholl, Susan, additional, Scott, April, additional, Shariff, Masroor, additional, Sharma, Shiwali, additional, Shin, Hyoung Doo, additional, Singh, Thakur Gurjeet, additional, Sinha, Namita, additional, Skosnik, Patrick D., additional, Bezerra, Ranilson de Souza, additional, Stairs, Dustin J., additional, Stefkov, Gjoshe, additional, Stein, Dan J., additional, Stern, Cristina A.J., additional, Stöllberger, Claudia, additional, Takahashi, Reinaldo N., additional, Tang, H.C., additional, Tarren, Josephine, additional, Tibbo, Philip G., additional, Tiwari, Vinod, additional, Torres, Carmen, additional, Trivelli, Federica, additional, Truman, Penelope, additional, Tsirimonaki, Emmanouella, additional, Vanneste, Sven, additional, Vansickel, Andrea R., additional, Vendruscolo, Leandro F., additional, Wai, Maria S.M., additional, Walter, Marc, additional, Waters, Karen A., additional, Weiner, Jeffrey L., additional, Weinstein, Jodi J., additional, Weisberg, Jordyn, additional, Whitaker, Annie M., additional, Wolf-Stanton, Sarah, additional, Wu, Chen-Ying, additional, Wu, Sharon L., additional, Yang, Cheryl C.H., additional, Yang, Yen Kuang, additional, Yeshwant Tandel, Kirti, additional, Yew, D.T., additional, Yousefzadeh Fard, Yashar, additional, and Zhou, Yan, additional
- Published
- 2016
- Full Text
- View/download PDF
3. List of Contributors
- Author
-
Addy, Peter H., primary, Bowen, Scott, additional, Brady, Kathleen T., additional, Brašić, James Robert, additional, Büttner, Andreas, additional, Chan, Ryan H.A., additional, Ciraulo, Domenic A., additional, Compton, Wilson M., additional, Craige, Caryne P., additional, Cruz, Silvia L., additional, Drgon, Tomas, additional, D’Souza, Deepak Cyril, additional, Enman, Nicole M., additional, Evins, A. Eden, additional, Fantegrossi, William E., additional, Gentilello, Larry, additional, Herman, Aryeh I., additional, Kalant, Harold, additional, Kim, Jongho, additional, Kish, Stephen J., additional, Lopez, Marsha, additional, Madras, Bertha, additional, Martinez, Diana, additional, McCann, Una D., additional, Mendelson, John E., additional, Nichols, David E., additional, Oldham, Mark, additional, Schuman-Olivier, Zev, additional, Radhakrishnan, Rajiv, additional, Ranganathan, Mohini, additional, Ricaurte, George A., additional, Robinson, Cendrine, additional, Sewell, R. Andrew, additional, Skosnik, Patrick D., additional, Sofuoglu, Mehmet, additional, Stoeckel, Luke E., additional, Trifilieff, Pierre, additional, Uhl, George R., additional, Unterwald, Ellen M., additional, Walther, Donna, additional, Waters, Andrew J., additional, Weinberg, Naimah, additional, and Weisz, Erika, additional
- Published
- 2014
- Full Text
- View/download PDF
4. Cannabis, Cannabinoids, and the Association with Psychosis
- Author
-
Radhakrishnan, Rajiv, primary, Addy, Peter H., additional, Sewell, R. Andrew, additional, Skosnik, Patrick D., additional, Ranganathan, Mohini, additional, and D’Souza, Deepak Cyril, additional
- Published
- 2014
- Full Text
- View/download PDF
5. Assessment of transient dopamine responses to smoked cannabis.
- Author
-
Calakos KC, Liu H, Lu Y, Anderson JM, Matuskey D, Nabulsi N, Ye Y, Skosnik PD, D'Souza DC, Morris ED, Cosgrove KP, and Hillmer AT
- Subjects
- Adult, Corpus Striatum diagnostic imaging, Dopamine, Humans, Positron-Emission Tomography, Raclopride, Young Adult, Cannabis, Marijuana Smoking, Ventral Striatum
- Abstract
Background: Dopaminergic mechanisms that may underlie cannabis' reinforcing effects are not well elucidated in humans. This positron emission tomography (PET) imaging study used the dopamine D
2/3 receptor antagonist [11 C]raclopride and kinetic modelling testing for transient changes in radiotracer uptake to assess the striatal dopamine response to smoked cannabis in a preliminary sample., Methods: PET emission data were acquired from regular cannabis users (n = 14; 7 M/7 F; 19-32 years old) over 90 min immediately after [11 C]raclopride administration (584 ± 95 MBq) as bolus followed by constant infusion (Kbol = 105 min). Participants smoked a cannabis cigarette, using a paced puff protocol, 35 min after scan start. Plasma concentrations of Δ9 -THC and metabolites and ratings of subjective "high" were collected during imaging. Striatal dopamine responses were assessed voxelwise with a kinetic model testing for transient reductions in [11 C]raclopride binding, linear-parametric neurotransmitter PET (lp-ntPET) (cerebellum as a reference region)., Results: Cannabis smoking increased plasma Δ9 -THC levels (peak: 0-10 min) and subjective high (peak: 0-30 min). Significant clusters (>16 voxels) modeled by transient reductions in [11 C]raclopride binding were identified for all 12 analyzed scans. In total, 26 clusters of significant responses to cannabis were detected, of which 16 were located in the ventral striatum, including at least one ventral striatum cluster in 11 of the 12 analyzed scans., Conclusions: These preliminary data support the sensitivity of [11 C]raclopride PET with analysis of transient changes in radiotracer uptake to detect cannabis smoking-induced dopamine responses. This approach shows future promise to further elucidate roles of mesolimbic dopaminergic signaling in chronic cannabis use. ClinicalTrials.gov Identifier: NCT02817698., (Copyright © 2021 Elsevier B.V. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
6. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
- Author
-
D'Souza DC, Cortes-Briones J, Creatura G, Bluez G, Thurnauer H, Deaso E, Bielen K, Surti T, Radhakrishnan R, Gupta A, Gupta S, Cahill J, Sherif MA, Makriyannis A, Morgan PT, Ranganathan M, and Skosnik PD
- Subjects
- Adolescent, Adult, Amidohydrolases, Double-Blind Method, Humans, Male, Marijuana Smoking, Middle Aged, Treatment Outcome, Urea administration & dosage, Young Adult, Cannabis, Marijuana Abuse drug therapy, Pyridazines administration & dosage, Substance Withdrawal Syndrome, Urea analogs & derivatives
- Abstract
Background: Cannabis is one of the most widely used drugs worldwide. Cannabis use disorder is characterised by recurrent use of cannabis that causes significant clinical and functional impairment. There are no approved pharmacological treatments for cannabis use disorder. One approach is to potentiate endocannabinoid signalling by inhibiting fatty acid amide hydrolase (FAAH), the enzyme that degrades the endocannabinoid anandamide. We aimed to test the efficacy and safety of the FAAH-inhibitor PF-04457845 in reduction of cannabis withdrawal and cannabis use in men who were daily cannabis users., Methods: We did a double-blind, placebo-controlled, parallel group phase 2a trial at one site in men aged 18-55 years with cannabis dependence according to DSM-IV criteria (equivalent to cannabis use disorder in DSM-5). After baseline assessments, participants were randomly assigned (2:1) to receive PF-04457845 (4 mg per day) or placebo using a fixed block size of six participants, stratified by severity of cannabis use and desire to quit. Participants were admitted to hospital for 5 days (maximum 8 days) to achieve abstinence and precipitate cannabis withdrawal, after which they were discharged to continue the remaining 3 weeks of treatment as outpatients. The primary endpoints were treatment-related differences in cannabis withdrawal symptoms during hospital admission, and week 4 (end of treatment) self-reported cannabis use and urine THC-COOH concentrations in the intention-to-treat population. The study is registered at ClinicalTrials.gov, number NCT01618656., Findings: Between Sept 12, 2012, and Jan 18, 2016, 46 men were randomly assigned to PF-04457845 and 24 to placebo. Adherence to study medication was 88%, as confirmed by video-calling and pill count, and corroborated by corresponding drug and anandamide concentrations in blood. Relative to placebo, treatment with PF-04457845 was associated with reduced symptoms of cannabis withdrawal (first day of treatment mean symptom score 11·00 [95% CI 7·78-15·57] vs 6·04 [4·43-8·24]; difference 4·96 [0·71-9·21]; p
adj =0·048; second day of treatment 11·74 [8·28-16·66] vs 6·02 [4·28-8·47]; difference 5·73 [1·13-10·32]; padj =0·035) and related mood symptoms during the inpatient phase. Additionally, treatment with PF-04457845 was associated with lower self-reported cannabis use at 4 weeks (mean 1·27 joints per day [95% CI 0·82-1·97] vs 0·40 [0·25-0·62]; difference 0·88 [0·29-1·46]; p=0·0003) and lower urinary THC-COOH concentrations (mean 657·92 ng/mL [95% CI 381·60-1134·30] vs 265·55 [175·60-401·57]; difference 392·37 [17·55-767·18)]; p=0·009). Eight (17%) patients in the PF-04457845 group and four (17%) in the placebo group discontinued during the treatment period. During the 4-week treatment phase, 20 (43%) of 46 participants in the PF-04457845 group and 11 (46%) of 24 participants in the placebo group had an adverse event. There were no serious adverse events., Interpretation: PF-04457845, a novel FAAH inhibitor, reduced cannabis withdrawal symptoms and cannabis use in men, and might represent an effective and safe approach for the treatment of cannabis use disorder., Funding: United States National Institute of Drug Abuse (NIDA)., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
7. Marijuana and Madness: Associations Between Cannabinoids and Psychosis.
- Author
-
Ranganathan M, Skosnik PD, and D'Souza DC
- Subjects
- Humans, Cannabinoids adverse effects, Marijuana Abuse physiopathology, Psychoses, Substance-Induced physiopathology
- Published
- 2016
- Full Text
- View/download PDF
8. It's All in the Rhythm: The Role of Cannabinoids in Neural Oscillations and Psychosis.
- Author
-
Skosnik PD, Cortes-Briones JA, and Hajós M
- Subjects
- Attention drug effects, Cannabinoid Receptor Agonists pharmacology, Dronabinol pharmacology, Electroencephalography, Endocannabinoids adverse effects, Humans, Memory, Short-Term drug effects, Psychomotor Performance drug effects, Brain physiopathology, Cannabinoid Receptor Agonists adverse effects, Dronabinol adverse effects, Marijuana Smoking psychology, Psychotic Disorders physiopathology, Schizophrenia physiopathology
- Abstract
Evidence has accumulated over the past several decades suggesting that both exocannabinoids and endocannabinoids play a role in the pathophysiology of schizophrenia. The current article presents evidence suggesting that one of the mechanisms whereby cannabinoids induce psychosis is through the alteration in synchronized neural oscillations. Neural oscillations, particularly in the gamma (30-80 Hz) and theta (4-7 Hz) ranges, are disrupted in schizophrenia and are involved in various areas of perceptual and cognitive function. Regarding cannabinoids, preclinical evidence from slice and local field potential recordings has shown that central cannabinoid receptor (cannabinoid receptor type 1) agonists decrease the power of neural oscillations, particularly in the gamma and theta bands. Further, the administration of cannabinoids during critical stages of neural development has been shown to disrupt the brain's ability to generate synchronized neural oscillations in adulthood. In humans, studies examining the effects of chronic cannabis use (utilizing electroencephalography) have shown abnormalities in neural oscillations in a pattern similar to those observed in schizophrenia. Finally, recent studies in humans have also shown disruptions in neural oscillations after the acute administration of delta-9-tetrahydrocannabinol, the primary psychoactive constituent in cannabis. Taken together, these data suggest that both acute and chronic cannabinoids can disrupt the ability of the brain to generate synchronized oscillations at functionally relevant frequencies. Hence, this may represent one of the primary mechanisms whereby cannabinoids induce disruptions in attention, working memory, sensory-motor integration, and many other psychosis-related behavioral effects., (Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.
- Author
-
Cortes-Briones JA, Cahill JD, Skosnik PD, Mathalon DH, Williams A, Sewell RA, Roach BJ, Ford JM, Ranganathan M, and D'Souza DC
- Subjects
- Adolescent, Adult, Cerebral Cortex physiology, Dose-Response Relationship, Drug, Double-Blind Method, Electroencephalography, Female, Healthy Volunteers, Humans, Male, Psychiatric Status Rating Scales, Psychotic Disorders pathology, Young Adult, Cerebral Cortex drug effects, Dronabinol adverse effects, Hallucinogens adverse effects, Noise, Psychotic Disorders etiology
- Abstract
Background: Drugs that induce psychosis may do so by increasing the level of task-irrelevant random neural activity or neural noise. Increased levels of neural noise have been demonstrated in psychotic disorders. We tested the hypothesis that neural noise could also be involved in the psychotomimetic effects of delta-9-tetrahydrocannabinol (Δ(9)-THC), the principal active constituent of cannabis., Methods: Neural noise was indexed by measuring the level of randomness in the electroencephalogram during the prestimulus baseline period of an oddball task using Lempel-Ziv complexity, a nonlinear measure of signal randomness. The acute, dose-related effects of Δ(9)-THC on Lempel-Ziv complexity and signal power were studied in humans (n = 24) who completed 3 test days during which they received intravenous Δ(9)-THC (placebo, .015 and .03 mg/kg) in a double-blind, randomized, crossover, and counterbalanced design., Results: Δ(9)-THC increased neural noise in a dose-related manner. Furthermore, there was a strong positive relationship between neural noise and the psychosis-like positive and disorganization symptoms induced by Δ(9)-THC, which was independent of total signal power. Instead, there was no relationship between noise and negative-like symptoms. In addition, Δ(9)-THC reduced total signal power during both active drug conditions compared with placebo, but no relationship was detected between signal power and psychosis-like symptoms., Conclusions: At doses that produced psychosis-like effects, Δ(9)-THC increased neural noise in humans in a dose-dependent manner. Furthermore, increases in neural noise were related with increases in Δ(9)-THC-induced psychosis-like symptoms but not negative-like symptoms. These findings suggest that increases in neural noise may contribute to the psychotomimetic effects of Δ(9)-THC., (Published by Elsevier Inc.)
- Published
- 2015
- Full Text
- View/download PDF
10. Testing differences in the activity of event-related potential sources: important implications for clinical researchers.
- Author
-
Cortes-Briones JA, Cahill JD, Ranganathan M, Sewell RA, D'Souza DC, and Skosnik PD
- Subjects
- Animals, Biomedical Research methods, Humans, Biomedical Research standards, Evoked Potentials physiology, Research Personnel standards
- Published
- 2015
- Full Text
- View/download PDF
11. Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users.
- Author
-
Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH, Zheng QH, Federici LA, Patton EA, Herring CM, and Yoder KK
- Subjects
- Adolescent, Adult, Corpus Striatum diagnostic imaging, Dopamine metabolism, Humans, Male, Marijuana Abuse diagnostic imaging, Radionuclide Imaging, Corpus Striatum metabolism, Marijuana Abuse metabolism, Marijuana Smoking metabolism, Receptors, Dopamine D2 metabolism, Receptors, Dopamine D3 metabolism
- Abstract
Background: Although the incidence of cannabis abuse/dependence in Americans is rising, the neurobiology of cannabis addiction is not well understood. Imaging studies have demonstrated deficits in striatal D(2)/D(3) receptor availability in several substance-dependent populations. However, this has not been studied in currently using chronic cannabis users., Objective: The purpose of this study was to compare striatal D(2)/D(3) receptor availability between currently using chronic cannabis users and healthy controls., Methods: Eighteen right-handed males age 18-34 were studied. Ten subjects were chronic cannabis users; eight were demographically matched controls. Subjects underwent a [(11)C]raclopride (RAC) PET scan. Striatal RAC binding potential (BP(ND)) was calculated on a voxel-wise basis. Prior to scanning, urine samples were obtained from cannabis users for quantification of urine Δ-9-tetrahydrocannabinol (THC) and THC metabolites (11-nor-Δ-9-THC-9-carboxylic acid; THC-COOH and 11-hydroxy-THC;OH-THC)., Results: There were no differences in D(2)/D(3) receptor availability between cannabis users and controls. Voxel-wise analyses revealed that RAC BP(ND) values were negatively associated with both urine levels of cannabis metabolites and self-report of recent cannabis consumption., Conclusions: In this sample, current cannabis use was not associated with deficits in striatal D(2)/D(3) receptor availability. There was an inverse relationship between chronic cannabis use and striatal RAC BP(ND). Additional studies are needed to identify the neurochemical consequences of chronic cannabis use on the dopamine system., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
12. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.
- Author
-
Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, and D'Souza DC
- Subjects
- Administration, Inhalation, Adult, Cardiovascular System drug effects, Cognition drug effects, Cross-Over Studies, Dose-Response Relationship, Drug, Drug Monitoring methods, Electroencephalography methods, Euphoria drug effects, Female, Hallucinogens administration & dosage, Hallucinogens adverse effects, Hallucinogens blood, Humans, Hydrocortisone blood, Male, Perception drug effects, Prolactin blood, Psychiatric Status Rating Scales, Receptors, Opioid, kappa agonists, Sensation drug effects, Diterpenes, Clerodane administration & dosage, Diterpenes, Clerodane adverse effects, Diterpenes, Clerodane blood, Illicit Drugs, Psychoses, Substance-Induced blood, Psychoses, Substance-Induced diagnosis, Psychoses, Substance-Induced physiopathology, Psychoses, Substance-Induced psychology
- Abstract
Background: Salvia divinorum (Salvia) is an increasingly popular recreational drug amongst adolescents and young adults. Its primary active ingredient, Salvinorin A (SA)-a highly selective agonist at the κ opiate receptor-is believed to be one of the most potent naturally occurring hallucinogens. However, there is little experimental data on the effects of SA in humans., Methods: In a 3-day, double-blind, randomized, crossover, counterbalanced study, the behavioral, subjective, cognitive, psychophysiological, and endocrine effects of 0 mg, 8 mg, and 12 mg of inhaled SA were characterized in 10 healthy individuals who had previously used Salvia., Results: SA produced psychotomimetic effects and perceptual alterations, including dissociative and somaesthetic effects, increased plasma cortisol and prolactin, and reduced resting electroencephalogram spectral power. The SA administration was associated with a rapid increase of its levels in the blood. SA did not produce euphoria, cognitive deficits, or changes in vital signs. The effects were transient and not dose-related. SA administration was very well-tolerated without acute or delayed adverse effects., Conclusions: SA produced a wide range of transient effects in healthy subjects. The perceptual altering effects and lack of euphoric effects would explain its intermittent use pattern. Such a profile would also suggest a low addictive potential similar to other hallucinogens and consistent with κ opiate receptor agonism. Further work is warranted to carefully characterize a full spectrum of its effects in humans, to elucidate the underlying mechanisms involved, and to explore the basis for individual variability in its effects., (Copyright © 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
13. Cannabinoids, working memory, and schizophrenia.
- Author
-
Skosnik PD, Ranganathan M, and D'Souza DC
- Subjects
- Humans, Male, Cerebellum drug effects, Cerebral Cortex drug effects, Dronabinol pharmacology, Hallucinogens pharmacology, Memory, Short-Term drug effects, Recognition, Psychology drug effects
- Published
- 2012
- Full Text
- View/download PDF
14. The effect of cannabis use and gender on the visual steady state evoked potential.
- Author
-
Skosnik PD, Krishnan GP, Vohs JL, and O'Donnell BF
- Subjects
- Adolescent, Adult, Analysis of Variance, Brain Mapping, Demography, Electroencephalography methods, Female, Humans, Male, Photic Stimulation methods, Reaction Time physiology, Spectrum Analysis, Evoked Potentials, Visual physiology, Marijuana Abuse physiopathology, Sex Characteristics, Visual Perception physiology
- Abstract
Objective: Cannabis use often induces subjective distortions of perception. However, little work has been done examining the electroencephalographic (EEG) correlates of early sensory processing in cannabis users. The present study therefore examined visual function in cannabis users as assessed via the steady state visual evoked potential. (SSVEP)., Methods: SSVEPs were examined in current cannabis users (n = 17; 59% male; mean age = 23.2 (S.D. = 5.3)) and drug-naive controls (n = 16; 38% male; mean age = 21.3 (S.D. = 3.1)) to periodic photic stimulation presented at 18 and 25 Hz. The visual SSVEP was quantified via spectral power and the phase-locking factor (PLF) at each frequency of stimulation. The transient N160 event-related potential (ERP) was also evaluated at stimulus onset., Results: The results showed that for both frequencies, female subjects in general displayed larger visual SSVEPs. A significant gender X group interaction also occurred at 18 Hz of stimulation, and age of onset of cannabis use positively correlated with 18 Hz spectral power values. Finally, the transient N160 component was shown to be reduced in cannabis users, regardless of gender., Conclusions: The present study was the first to demonstrate altered visual SSVEPs in cannabis users, and extends previous research demonstrating increased steady state responses in female subjects. While decreased SSVEPs provide initial evidence of altered oscillatory properties in primary visual circuits, reduction of the transient N160 component suggests disruption of later-stage visual processing in cannabis users., Significance: These data provide evidence of cannabinoid modulation of sensory/perceptual function in the visual system, and indicates that cannabis use may affect the oscillatory properties of sensory cortical circuits.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.